A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer

Share :
Published: 30 Sep 2012
Views: 5714
Dr Christophe Massard - Institute Gustave Roussy, Paris, France

During a press conference at ESMO 2012 in Vienna, Dr Christophe Massard discusses a dose-escalation trial where 87% of 15 patients who received a novel androgen receptor agonist called ODM-201 experienced a PSA decrease at 12 weeks.


ecancerNews coverage of ESMO 2012